Adding romidepsin to frontline chemotherapy does not improve progression-free survival (PFS) in patients with peripheral T-cell lymphoma (PTCL), according to phase 2 results presented at the 2021 American Society of Hematology (ASH) Annual Meeting.The study’s..

The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older. The FDA also extended the psoriatic arthritis (PsA) indica..

Topical pimecrolimus 1% treatment had unsatisfactory results, while combination microneedling and topical pimecrolimus treatment showed a favorable outcome. Although there is no cure for vitiligo, microneedling has been shown to be effective in the repigmentat..

Highlights • Fluralaner, an isoxazoline ectoparasiticide, potently inhibits GABARs.• Inhibition by fluralaner progresses over time after every GABAR activation.• Fluralaner does not inhibit the GABA response in the GABAR resting state.• Fluralaner hardly d..

The use of the immunosuppressive agent vedolizumab in treatment of gastrointestinal (GI) acute graft-versus-host disease (aGVHD) in 3 pediatric patients was described in a recent case report published in the International Journal of Hematology. This treatment ..

Daratumumab plus lenalidomide and dexamethasone shows improvement in progression-free survival in patients with newly diagnosed multiple myeloma, according to interim results published in The Lancet Oncology.MAIA is a randomized, phase 3, open-label trial with..

Adding ramucirumab to paclitaxel as second-line therapy improved progression-free survival (PFS) in Asian patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to research published in The Lancet Gastroenterology & Hep..

Results from a Phase 0/1 clinical trial of the breast cancer drug ribociclib (Kisqali®; Novartis), a kinase inhibitor, plus everolimus (Afinitor®; Novartis), a derivative of sirolimus and an inhibitor of tor serine-threonine kinases, in patient..

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European ..